| Title | [Drugs for osteoporosis under development] | | Author(s) | Masuda H, Tanaka S | | Institution | Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo. | | Source | Nippon Rinsho 2009 May; 67(5):980-4. | | Abstract | Osteoporosis is a disease in which the density and quality of bone is reduced, leading to an increase in fragility fractures. Osteoporosis is a major health threat affecting more than 10 million people in Japan. Emerging evidence has shown that anti-resorptive drugs such as bisphosphonates and raloxifene efficiently increase bone mass and prevent osteoporotic fractures by maintaining bone homeostasis. In addition, anabolic drugs such as parathyroid hormone and novel anti-resorptive drugs such as anti-RANKL drugs and cathepsin K inhibitors, which directly target osteoclasts are under development. In this review, we would like to summarize the current status of the development of anti-osteoporotic drugs. | | Language | jpn | | Pub Type(s) | English Abstract
Journal Article
| | PubMed ID | 19432120 |
|
